Lung EpiCheck Biomarkers Development Study
Status unconfirmed
Conditions studied: Lung Cancer
In brief
This study is part of the development of a non-invasive lung cancer screening test which aim to identify early-stage lung cancer in patients at high risk for lung cancer.
Key facts
- Study ID
- NCT06245876
- Run by
- Nucleix Ltd.
- People needed
- 6000
- Starts
- 2022-05-17
- Expected to finish
- 2025-12-31
- Last updated by the study team
- 2024-02-12
Who can join
Age: 20 and older, up to 80. Sex: any. Healthy volunteers: accepted.
Where it is running
- ZGT Medical Center — Hengelo, Netherlands (enrolling)
- Emerald Coast OBGYN — Panama City, Florida, United States (enrolling)
- Ochsner LSU Health Shreveport - Regional Urology — Shreveport, Louisiana, United States (enrolling)
- Life Spring Clinical Research — Miami, Florida, United States (enrolling)
- Michigan Institute of Urology, P.C. — Troy, Michigan, United States (enrolling)
- Urology San Antonio — San Antonio, Texas, United States (enrolling)
- National Koranyi Institute for Pulmonology — Budapest, Hungary (enrolling)
- Carmel Medical Center — Haifa, Israel (enrolling)
- Sourasky Medical Center — Tel Aviv, Israel (enrolling)
- Comprehensive Urology — Southfield, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.